Eli Lilly's Zepbound gains sleep apnea indication
Hawkinsight
2024-12-21 09:07:50
1.64W
NicolasMcComber/iStock via Getty Images
- The U.S. FDA has approved an additional indication for Eli Lilly's (NYSE:LLY) Zepbound (tirzepatide) to include obstructive sleep apnea in obese adults.
- The approval was based on results from a phase 3 trial that showed the drug benefitted individuals irregardless
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
